ABC | Volume 115, Nº2, Agosto 2020

Ponto de Vista Feitosa et al. Tratamento Medicamentoso da Hipertensão Arq Bras Cardiol. 2020; 115(2):270-272 1. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124(7):1061-70. 2. MalachiasMVB, JardimPCV, Almeida FA, Lima Jr E, FeitosaGS. 7th Brazilian Guideline of Arterial Hypertension: Chapter 7 - Pharmacological Treatment. Arq Bras Cardiol. 2016;107(3 Suppl 3):35-43. 3. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199-2269. 4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESHGuidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. 5. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(1008):2059–68. 6. Krieger EM, Drager LF , Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71:681–90. 7. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475–81. 8. Précoma DB, Oliveira GMM, Simão AF, Dutra OP, Coelho OR, Izar MCO, et al. Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia – 2019. Arq Bras Cardiol. 2019;113(4):787-891. 9. Passarelli Jr O. Resistant hypertension: how I treat. Rev Bras Hipertens. 2011;18(4):160-2. 10. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359:2417-28. 11. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison- Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53-e90. 12. ManciaG,FagardR,NarkiewiczK,Redon J,ZanchettiA,BöhmM,etal.2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-2219. 13. Tavares A, Brandão AA, Sanjuliani AF, Nogueira AR, Machado CA, Poli-de- Figueiredo E, et al. VI Diretrizes Brasileiras deHipertensão Arterial. Arq Bras Cardiol. 2010;95(1 supl 1):1-51. 14. Alessi A, Brandão AA, Coca A, Cordeiro AC, Nogueira AR, Diógenes de Magalhães F , et al. First Brazilian position on resistant hypertension. Arq Bras Cardiol. 2012;99(1):576-85. 15. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):46475. 16. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(3):257-63. 17. Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017 Apr 15;233:113-17. 18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283(15):1967–75. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons Contribuição dos Autores Concepção e desenho da pesquisa: Feitosa ADM, Mota-Gomes M, Passarelli Júnior O, Barroso WKS, Miranda RD, Barbosa ECD, Brandão AA, Nadruz W; Redação do manuscrito: Feitosa ADM, Nadruz W; Revisão crítica do manuscrito quanto ao conteúdo intelectual importante: Mota-Gomes M, Passarelli Júnior O, Barroso WKS, Miranda RD, Barbosa ECD, Brandão AA. Potencial Conflito de Interesses Audes Diógenes Magalhães Feitosa - Servier, Novartis, EMS e Omron (palestras e patrocínio em congressos) Marco Mota Gomes - Biolab, Torrent, Abbott, Novartis, Astra, Libbs, Omron e Servier (palestras, separatas e patrocínio em congressos) Weimar Kunz Sebba Barroso - Servier, Novartis, EMS, Bayer, Amgen, OMRON (palestras, patrocínio em congressos e pesquisa clínica) Roberto Dischinger Miranda - Servier, Boehringer, Sanofi, Biolab, Bayer (estudo clínico, palestras, separata e patrocínio em congresso) Eduardo Costa Duarte Barbosa - Servier, Medley, EMS e Torrent (palestras, separatas e patrocínio em congressos) Andrea A. Brandão - Servier, Libbs, Novartis, EMS (palestras e patrocínio em congressos). Fontes de Financiamento O presente estudo foi parcialmente financiado pelo CNPq (306154/2017-0). Vinculação Acadêmica Este artigo é parte de tese de Doutorado de Audes D. M. Feitosa pela Universidade Federal de Pernambuco. 272